Multidisciplinar y Management of Pancreatic Cancer

[1]  J. Armitage,et al.  Abeloff's Clinical Oncology: Fifth Edition , 2013 .

[2]  Vic Velanovich,et al.  Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. , 2012, Journal of the American College of Surgeons.

[3]  M. Büchler,et al.  Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. , 2012, JAMA.

[4]  M. Falconi,et al.  Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[6]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  K. Horton,et al.  Pancreatic surgery for the radiologist, 2011: an illustrated review of classic and newer surgical techniques for pancreatic tumor resection. , 2011, AJR. American journal of roentgenology.

[8]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Diaz,et al.  A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma , 2011, Cancer Chemotherapy and Pharmacology.

[10]  M. Hidalgo,et al.  A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer , 2011, Molecular Cancer Therapeutics.

[11]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[12]  R. Wahl,et al.  The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. , 2011, Seminars in radiation oncology.

[13]  R. Abrams,et al.  Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  K. Lillemoe,et al.  A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation , 2011, Annals of surgery.

[15]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[16]  D. Pleskow,et al.  Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. , 2010, International journal of radiation oncology, biology, physics.

[17]  E. O’Reilly.  Refinement of adjuvant therapy for pancreatic cancer. , 2010, JAMA.

[18]  H. Friess,et al.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.

[19]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[20]  Paolo Francescon,et al.  Unresectable Locally Advanced Pancreatic Cancer: A Multimodal Treatment Using Neoadjuvant Chemoradiotherapy (Gemcitabine Plus Stereotactic Radiosurgery) and Subsequent Surgical Exploration , 2010, Annals of Surgical Oncology.

[21]  Pierre-Alexandre Poletti,et al.  Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management. , 2010, World journal of gastroenterology.

[22]  M. Salamat,et al.  Robbins and Cotran: Pathologic Basis of Disease, 8th Edition , 2010 .

[23]  W. Scheithauer,et al.  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Catalano,et al.  Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Choti,et al.  Risk Factors for Pancreatic Leak After Distal Pancreatectomy , 2009, Annals of surgery.

[26]  Kenneth J. Chang,et al.  Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.

[27]  M. Choti,et al.  Determining Pattern of Recurrence Following Pancreaticoduodenectomy and Adjuvant 5-Flurouracil-Based Chemoradiation Therapy: Effect of Number of Metastatic Lymph Nodes and Lymph Node Ratio , 2009, Journal of Gastrointestinal Surgery.

[28]  Daniel T Chang,et al.  Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas , 2009, Cancer.

[29]  R. Abrams,et al.  Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Twombly.  Adjuvant chemoradiation for pancreatic cancer: few good data, much debate. , 2008, Journal of the National Cancer Institute.

[31]  M. Ychou,et al.  Histopathological Response to Preoperative Chemoradiation for Resectable Pancreatic Adenocarcinoma: The French Phase II FFCD 9704-SFRO Trial , 2008, American journal of clinical oncology.

[32]  T. Desser,et al.  Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. , 2008, International journal of radiation oncology, biology, physics.

[33]  K. Goellner,et al.  Characterization of nonhost resistance of Arabidopsis to the Asian soybean rust. , 2008, Molecular plant-microbe interactions : MPMI.

[34]  B. Chauffert,et al.  Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  Jeffrey E. Lee,et al.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Malafa,et al.  PET/CT Fusion Scan Enhances CT Staging in Patients with Pancreatic Neoplasms , 2008, Annals of Surgical Oncology.

[38]  M. Schäfer,et al.  Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  K. Campbell,et al.  Evaluating the Impact of a Single-Day Multidisciplinary Clinic on the Management of Pancreatic Cancer , 2008, Annals of Surgical Oncology.

[40]  E. Touboul,et al.  Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Edgar Ben-Josef,et al.  Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Joel G Fletcher,et al.  Resectability of Presymptomatic Pancreatic Cancer and Its Relationship to Onset of Diabetes: A Retrospective Review of CT Scans and Fasting Glucose Values Prior to Diagnosis , 2007, The American Journal of Gastroenterology.

[43]  C. Ko,et al.  Accuracy of staging node-negative pancreas cancer: a potential quality measure. , 2007, Archives of surgery.

[44]  Douglas B. Evans,et al.  Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy , 2007, Cancer.

[45]  J. Quivey,et al.  A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. , 2007, International journal of radiation oncology, biology, physics.

[46]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Stocken,et al.  A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin , 2007, Annals of Surgical Oncology.

[48]  M. Desai,et al.  The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis , 2007, Cancer Chemotherapy and Pharmacology.

[49]  E. Touboul,et al.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Michael A. Choti,et al.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience , 2006, Journal of Gastrointestinal Surgery.

[51]  H. Einsele,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  A. Chang,et al.  Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. , 2005, International journal of radiation oncology, biology, physics.

[53]  Quynh-Thu Le,et al.  Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. , 2005, International journal of radiation oncology, biology, physics.

[54]  L. Case,et al.  Phase II Trial of Induction Gemcitabine/CPT-11 Followed by a Twice-Weekly Infusion of Gemcitabine and Concurrent External Beam Radiation for the Treatment of Locally Advanced Pancreatic Cancer , 2005, American journal of clinical oncology.

[55]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Christopher H. Crane,et al.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration , 2004, Journal of Gastrointestinal Surgery.

[57]  H. Friess,et al.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma , 2004, The British journal of surgery.

[58]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[59]  Albert C Koong,et al.  Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. , 2004, International journal of radiation oncology, biology, physics.

[60]  E. Ross,et al.  The Metastatic/Examined Lymph Node Ratio is an Important Prognostic Factor after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma , 2004, The American surgeon.

[61]  D. Lorenz,et al.  Long-term Results of Partial Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreatic Head: 25-Year Experience , 2003, World Journal of Surgery.

[62]  I Ihse,et al.  Influence of Resection Margins on Survival for Patients With Pancreatic Cancer Treated by Adjuvant Chemoradiation and/or Chemotherapy in the ESPAC-1 Randomized Controlled Trial , 2001, Annals of surgery.

[63]  J. Jeekel,et al.  Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. , 1999, Annals of surgery.

[64]  C. Charnsangavej,et al.  Survival following pancreaticoduodenectomy with resection of the superior mesenteric–portal vein confluence for adenocarcinoma of the pancreatic head , 1998, The British journal of surgery.

[65]  M. Talamini,et al.  Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. , 1997, Annals of surgery.

[66]  K. Bakkevold,et al.  Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla of Vater--the prognostic factors influencing the long-term results. A prospective multicentre study. , 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[67]  J. Paradelo,et al.  Patterns of failure after curative resection of pancreatic carcinoma , 1990, Cancer.

[68]  S. Ellenberg,et al.  Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. , 1985, Archives of surgery.

[69]  P. Engstrom,et al.  Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  J. Barkin,et al.  Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation + 5‐fluorouracil. The gastrointestinal tumor study group , 1981, Cancer.

[71]  Jeffrey E. Lee,et al.  Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer , 2011, Journal of Gastrointestinal Surgery.

[72]  T. Eberlein.  Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial , 2008 .

[73]  Matthew J Hayat,et al.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. , 2007, The oncologist.